Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variants compared with Alpha variant in vaccinated individuals.

Stijn P Andeweg,Chantal Reusken,Harry Vennema,Mirjam J Knol,Dirk Eggink,Dennis Schmitz,Irene Veldhuijzen,Florian Zwagemaker,Naomi Smorenburg,Djoo Dunk ,Senna Van Iersel ,L Marije Hofstra ,Suzan D Pas ,Karin Van Leeuwen ,Lilli Gard ,Jelle Koopsen ,Jessica De Beer ,Eveline Geubbels ,C Vermeulen ,J Polman ,Annemarie M J Wensing ,Adri Van Der Zanden ,Joep Stohr ,Igor A Sidorov ,Jozef Dingemans ,Lieke B Van Alphen ,Erley F Lizarazo Forero ,Brian Van Der Veer ,Richard Molenkamp ,Laura Manrho ,Marion Koopmans ,Jaco J Verweij ,Stefan A Boers ,Janneke Van Heereveld ,J.l Blussé Van Oud Alblas ,Willem J G Melchers ,Karim Hajji ,Sharon Van Den Brink ,Bas Van Der Veer ,Sander Schuurman ,David F Nieuwenhuijse ,Susan Hahné ,Anniek A N Tanja ,Rolina Van Gaalen ,Paul H M Savelkoul ,Lynn Aarts ,Monika A Fliss ,Jeroen Cremer ,Brechje De Gier ,M Mulder ,Bas B Oude Munnink ,Anne-Marie Van Den Brandt ,Susan Van Den Hof ,Jan Van De Kassteele ,Maarten Schipper ,Ryanne Jaarsma ,Lianne Koets ,Ivo Van Walle ,Priscila De Oliveira Bressane Lima ,Nadia Keijzer ,Jordy P M Coolen ,Remco Dijkman ,Tom Vreeswijk ,Birgit Van Benthem ,Erin Meijers ,Reina S Sikkema ,Hubert G M Niesters ,Arianne B Van Gageldonk-Lafeber ,Agnetha Hofhuis ,Pieter W Smit ,Menno D De Jong ,Janette Rahamat‐Langendoen ,Marco Koppelman ,Timor Faber ,Euníce Then ,K Freriks ,Annelies Kroneman ,Janke Schinkel ,Marcel Jonges ,Heiman Wertheim ,Sanne Bos ,Rob Schuurman ,Manon M.c Holstege ,Sara Wijburg ,Matthijs R.a Welkers ,Lisa Wijsman

doi:10.1126/scitranslmed.abn4338

Abstract

The extent to which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) break through infection- or vaccine-induced immunity is not well understood. We analyzed 28,578 sequenced SARS-CoV-2 samples from individuals with known immune status obtained through national community testing in the Netherlands from March to August 2021. We found evidence of an increased risk of infection by the Beta (B.1.351), Gamma (P.1), or Delta (B.1.617.2) variants compared to the Alpha (B.1.1.7) variant after vaccination. No clear differences were found between vaccines. However, the effect was larger in the first 14-59 days after complete vaccination compared to ≥60 days. In contrast to vaccine-induced immunity, there was no increased risk for re-infection with Beta, Gamma or Delta variants relative to Alpha variant in individuals with infection-induced immunity.

Full Text